Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSCPA.L Regulatory News (SCPA)

  • There is currently no data for SCPA

Trading Update

12 Feb 2020 07:00

RNS Number : 6939C
Scapa Group PLC
12 February 2020
 

12 February 2020

 

LEI No. 213800QIPVTK5ES5UU36

 

 

Scapa Group plc

 

Trading Update

 

Scapa Group plc (AIM: SCPA) provides an update on current trading ahead of its financial year-end on 31 March 2020.

 

The Group expects FY20 revenue to be approximately ÂŁ306 million, broadly in line with market expectations. However, trading profit is now expected to be approximately ÂŁ28 million, significantly below consensus.

 

Healthcare revenue is estimated to be approximately ÂŁ139 million, slightly ahead of market expectations and greater than last year despite the loss of the ConvaTec contract. Healthcare trading profit is expected to be lower than consensus, reflecting slower progress in reducing costs than expected at the time of the interim results. The Group continues to focus on our pipeline of new programs as we leverage our technologies and capabilities to drive our organic growth and reduce the cost of operations.

 

Industrial revenue is expected to be approximately ÂŁ168 million, which is slightly below market expectations but has a material impact on Group trading profit. This is primarily the result of adverse macroeconomic conditions, particularly in the automotive and specialty products markets.

 

The Group is focused on rigorous execution of the strategy as it continues to increase efficiency and convert its pipeline of opportunities to improve sales and margin performance. The Group expects the macro environment to remain challenging in some of the industrial markets in which it operates.

 

We believe that we have the right vision and strategy to capitalize on the outlook and opportunities for Healthcare and Industrial. Our Healthcare franchise is well positioned to benefit from the changes in the medical device market and whilst we expect the macro-environment to remain challenging, we will focus on cost reductions to drive the margin in Industrial to historical levels.

 

Scapa expects to report its full year results on 19 May 2020.

 

 

For further information:

 

Scapa Group plc

Heejae Chae - Group Chief Executive

Oskar Zahn - Chief Financial Officer

 

Tel: 0161 301 7430

Numis Securities Limited

(Nominated Adviser/Joint Broker)

 

Mark Lander, Freddie Barnfield

Tel: 020 7260 1000

Berenberg

(Joint Broker)

 

Chris Bowman, Toby Flaux

 

Tel: 020 3207 7800

FTI Consulting

(Media Relations)

 

Simon Conway, Victoria Foster Mitchell

Tel: 020 3727 1000

 

 

 

 

About Scapa Group plc

Scapa Group plc is a diversified Healthcare and Industrial company focused on bringing best-in-class innovation, design and manufacturing solutions to its customers.

 

Healthcare

Scapa Healthcare is the trusted strategic partner of choice for the world's leading companies in Advanced Wound Care, Consumer Wellness and Medical Device Fixation. We partner with the top global MedTech companies to develop and manufacture innovative skin friendly medical device fixation and topical solutions, from inception through to market delivery, from our state-of-the-art facilities.

 

For further information, please visit www.scapahealthcare.com

 

Industrial

Scapa Industrial is a global supplier of bonding solutions and manufacturer of adhesive-based products which offer meaningful value in industrial applications due to their lightweight, easy-to-apply properties. We are recognised for our unparalleled range of products, including adhesive tapes, films and foams, and we can engineer custom designs for even the most unique applications.

 

For further information, please visit www.scapaindustrial.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTEADAFFDDEEAA
Date   Source Headline
1st Dec 201510:11 amRNSHolding(s) in Company
1st Dec 201510:10 amRNSHolding(s) in Company
30th Nov 201510:34 amRNSTotal Voting Rights
24th Nov 20157:00 amRNSInterim Results
3rd Nov 20154:55 pmRNSHolding(s) in Company
3rd Nov 20154:54 pmRNSShareholder Circular Posted
13th Oct 20157:00 amRNSTrading Statement
10th Sep 20151:03 pmRNSAdditional Listing
9th Sep 20159:48 amRNSHolding(s) in Company
1st Sep 20153:57 pmRNSBlocklisting Interim Review
1st Sep 20153:29 pmRNSAdditional Listing
11th Aug 20151:28 pmRNSAdditional Listing
10th Aug 20159:46 amRNSDirector/PDMR Shareholding
23rd Jul 20159:21 amRNSDirector/PDMR Shareholding
21st Jul 20157:00 amRNSAGM Statement
14th Jul 20153:56 pmRNSAdditional Listing
13th Jul 20151:26 pmRNSHolding(s) in Company
2nd Jul 201511:15 amRNSAdditional Listing
17th Jun 20157:00 amRNSHealthcare Site Visit
16th Jun 20159:15 amRNSAdditional Listing
10th Jun 20152:54 pmRNSHolding(s) in Company
5th Jun 20159:01 amRNSHolding(s) in Company
4th Jun 20159:31 amRNSHolding(s) in Company
3rd Jun 20158:59 amRNSHolding(s) in Company
27th May 20157:00 amRNSFinal Results
28th Apr 20153:27 pmRNSAdditional Listing
9th Apr 20157:00 amRNSTrading Statement
7th Apr 20154:38 pmRNSHolding(s) in Company
7th Apr 20153:43 pmRNSAdditional Listing
31st Mar 20159:12 amRNSTotal Voting Rights
30th Mar 20154:02 pmRNSAdditional Listing
30th Mar 20152:58 pmRNSDirector/PDMR Shareholding
18th Mar 20154:45 pmRNSHolding(s) in Company
16th Mar 20154:20 pmRNSAdditional Listing
10th Mar 20154:10 pmRNSAdditional Listing
9th Mar 20157:00 amRNSHolding(s) in Company
5th Mar 20157:00 amRNSDirector/PDMR Shareholding
5th Mar 20157:00 amRNSDirector/PDMR Shareholding
4th Mar 20157:00 amRNSDirector/PDMR Shareholding
2nd Mar 20153:58 pmRNSAdditional Listing
2nd Mar 20157:00 amRNSAcquisition
23rd Feb 20159:08 amRNSHolding(s) in Company
16th Feb 20159:01 amRNSHolding(s) in Company
13th Feb 20159:09 amRNSHolding(s) in Company
11th Feb 201510:52 amRNSHolding(s) in Company
9th Feb 20151:35 pmRNSHolding(s) in Company
9th Feb 201510:33 amRNSBlocklisting Interim Review
4th Feb 201512:18 pmRNSHolding(s) in Company
23rd Jan 20159:59 amRNSHolding(s) in Company
31st Dec 201412:02 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.